Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Roudy who wrote (1601)	10/21/1998 5:15:00 PM
From: Douglas Babbin	Respond to of 1762

IDEC reported EPS of .08 , .17 higher than Merrill Lynch's forecast of a loss of .09. The increase in earnings was due to increased profitability from the Rituxan joint venture, lower costs and a $2MM milestone payment. From what I have read Merrill has a price objective of $45. Off label use of Rituxan has increased, as oncologists have become more comfortable using the treatment. IDEC now has five novel compounds in clinical development. IDEC-Y2B8 is currently in Phase III testing and the BLA is expected to be filed with the FDA by the end of 1999.